On Wednesday, Inari Medical stock received an upgrade to its Relative Strength (RS) Rating, from 65 to 72.
This proprietary rating measures technical performance by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Over 100 years of market history shows that the best-performing stocks tend to have an RS Rating north of 80 as they launch their largest climbs. See if Inari Medical stock can continue to show renewed price strength and hit that benchmark.
How To Invest In Stocks In Both Bull And Bear Markets
Is Inari Medical Stock A Buy?
Inari Medical stock is now considered extended and out of buy range after clearing a 53.67 buy point in a first-stage cup with handle. See if the medical stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
The medical device company posted 0% earnings growth in the latest quarterly report. Revenue rose 21%.
Inari Medical stock earns the No. 50 rank among its peers in the Medical-Products industry group. Globus Medical, LeMaitre Vascular and Insulet are among the top 5 highly rated stocks within the group.
